Tachyphylaxis after Repeated Antidepressant Drug Exposure in Patients with Recurrent Major Depressive Disorder
The DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
Abstract
Objective: The aim of this post hoc analysis was to examine whether tachyphylaxis occurs after repeated courses of antidepressant drug therapy. Method: 276 patients with major depressive disorder (MDD) were treated with sertraline (150–200 mg daily) for 8 weeks. Patients with persistent MDD after sertraline therapy were randomized to continuation therapy with either sertraline plus atomoxetine (n = 72) or sertraline plus placebo (n = 74) for 8 additional weeks. Logistic regression was used to test the hypothesis that an increase in prior antidepressant drug exposure is associated with a reduced responsiveness to sertraline therapy. Results: The number of prior antidepressant drug exposures was negatively associated with response to initial sertraline therapy (odds ratio = 0.81, p = 0.0035). The odds ratio indicates a 19.9% reduced likelihood of response with each prior antidepressant treatment trial. In contrast, the number of prior antidepressant treatment trials was not associated with response to continuation sertraline plus atomoxetine or sertraline plus placebo therapy. Conclusion: This observation supports the hypothesis that tachyphylaxis may develop after repeated antidepressant drug trials.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Prior use of AD has been found to be related to resistance to AD that differed from those administered during the first trials.”
From May antidepressant drugs worsen the conditions they are supposed to treat? The clinical foundations of the oppositional model of tolerance (2020) · cites this paper as [25]
Citations
Cites
Rush, A. J., Trivedi, M. H., Wisniewski, S. R., Nierenberg, A. A., Stewart, J. W., Warden, D., Niederehe, G., Thase, M. E., Lavori, P. W., Lebowitz, B. D., et al. (2006) · American Journal of Psychiatry · doi:10.1176/ajp.2006.163.11.1905 · Cited by 5,643
Self-citationTrivedi, M. H., Rush, A. J., Wisniewski, S. R., Nierenberg, A. A., Warden, D., Ritz, L., Norquist, G., Howland, R. H., Lebowitz, B., McGrath, P. J., et al. (2006) · American Journal of Psychiatry · doi:10.1176/appi.ajp.163.1.28 · Cited by 3,879
Self-citationAllelic Variation of Human Serotonin Transporter Gene Expression
Heils, A., Teufel, A., Petri, S., Stöber, G., Riederer, P., Bengel, D., & Lesch, K. P. (1996) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1996.66062621.x · Cited by 2,221
Wilamowska (2010) · doi:10.1001/archpsyc.1988.01800320058007 · Cited by 2,115 · cited 1×
“was used to confirm diagnostic eligibility for the study. Symptom severity was assessed using the 17-item Hamilton Depression Rating (HAM-D 17) scale [”
MethodGoldapple, K., Segal, Z., Garson, C., Lau, M., Bieling, P., Kennedy, S., & Mayberg, H. (2004) · Archives of General Psychiatry · doi:10.1001/archpsyc.61.1.34 · Cited by 1,068
Bupropion-SR, Sertraline, or Venlafaxine-XR after Failure of SSRIs for Depression
Rush, A. J., Trivedi, M. H., Wisniewski, S. R., Stewart, J. W., Nierenberg, A. A., Thase, M. E., Ritz, L., Biggs, M. M., Warden, D., Luther, J. F., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa052963 · Cited by 1,033
Self-citationRemission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors
Thase, M. E., Entsuah, A. R., & Rudolph, R. L. (2001) · British Journal of Psychiatry · doi:10.1192/bjp.178.3.234 · Cited by 801
Smeraldi, E., Zanardi, R., Benedetti, F., Bella, D. D., Perez, J., & Catalano, M. (1998) · Molecular Psychiatry · doi:10.1038/sj.mp.4000425 · Cited by 614 · cited 1×
“There is considerable debate as to whether tachyphylaxis to antidepressant drug therapy results from a genetic predisposition [”
BackgroundTreatment-Resistant Depression
(2015) · Encyclopedia of Psychopharmacology · doi:10.1007/978-3-642-36172-2_200431 · Cited by 488
Pollock, B. (2000) · Neuropsychopharmacology · doi:10.1016/s0893-133x(00)00132-9 · Cited by 415
Serotonin transporter gene polymorphism and antidepressant response
Kim, D. K., Lim, S.-W., Lee, S., Sohn, S. E., Kim, S., Hahn, C. G., & Carroll, B. J. (2000) · NeuroReport · doi:10.1097/00001756-200001170-00042 · Cited by 398
Fava, M., Rush, A. J., Wisniewski, S. R., Nierenberg, A. A., Alpert, J. E., McGrath, P. J., Thase, M. E., Warden, D., Biggs, M., Luther, J. F., et al. (2006) · American Journal of Psychiatry · doi:10.1176/ajp.2006.163.7.1161 · Cited by 362
Self-citationMcGrath, P. J., Stewart, J. W., Fava, M., Trivedi, M. H., Wisniewski, S. R., Nierenberg, A. A., Thase, M. E., Davis, L., Biggs, M. M., Shores-Wilson, K., et al. (2006) · American Journal of Psychiatry · doi:10.1176/ajp.2006.163.9.1531 · Cited by 350
Self-citationMurphy, G. M., Hollander, S. B., Rodrigues, H. E., Kremer, C., & Schatzberg, A. F. (2004) · Archives of General Psychiatry · doi:10.1001/archpsyc.61.11.1163 · Cited by 275
Self-citationBasic pharmacologic mechanisms involved in benzodiazepine tolerance and withdrawal
Bateson, A. (2002) · Current Pharmaceutical Design · doi:10.2174/1381612023396681 · Cited by 240 · cited 1×
“Finally, other lines of evidence suggest that stepwise tachyphylaxis may result from antidepressant-induced physiological adaptation. For example, repetitive administration of benzodiazepines may be associated with physiological adaptation in γ-aminobutyric acid receptors that results in drug tolerance and tachyphylax…”
BackgroundYoshida, K., Ito, K., Sato, K., Takahashi, H., Kamata, M., Higuchi, H., Shimizu, T., Itoh, K., Inoue, K., Tezuka, T., et al. (2002) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/s0278-5846(01)00287-1 · Cited by 226
Can long-term treatment with antidepressant drugs worsen the course of depression?
Fava, G. A. (2003) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v64n0204 · Cited by 223
Reimherr, F. W., Amsterdam, J. D., Quitkin, F. M., Rosenbaum, J. F., Fava, M., Zajecka, J., Beasley, Jr., Michelson, D., Roback, P., & Sundell, K. (1998) · American Journal of Psychiatry · doi:10.1176/ajp.155.9.1247 · Cited by 204
Self-citationVenlafaxine for Treatment-Resistant Unipolar Depression
NIERENBERG, A. A., FEIGHNER, J. P., RUDOLPH, R., COLE, J. O., & SULLIVAN, J. (1994) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199412000-00008 · Cited by 198
Self-citationJacobs, N., Kenis, G., Peeters, F., Derom, C., Vlietinck, R., & van Os, J. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.9.989 · Cited by 192
Neumeister, A., Hu, X.-Z., Luckenbaugh, D. A., Schwarz, M., Nugent, A. C., Bonne, O., Herscovitch, P., Goldman, D., Drevets, W. C., & Charney, D. S. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.9.978 · Cited by 161
Clinical issues in long-term treatment with antidepressants.
Zajecka, J. M. (2000) · PubMed · Cited by 144
Extrapyramidal Symptoms in Patients Treated With Risperidone
Simpson, G. M., & Lindenmayer, J.-P. (1997) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199706000-00010 · Cited by 130
Maier, W., & Philipp, M. (1985) · Pharmacopsychiatry · doi:10.1055/s-2007-1017335 · Cited by 117
Neuroleptic-Induced Acute Extrapyramidal Syndromes and Tardive Dyskinesia
Casey, D. E. (1993) · Psychiatric Clinics of North America · doi:10.1016/s0193-953x(18)30166-7 · Cited by 107
Nortriptyline for Treatment-Resistant Depression
Nierenberg, A. A., Papakostas, G. I., Petersen, T., Kelly, K. E., Iacoviello, B. M., Worthington, J. J., Tedlow, J., Alpert, J. E., & Fava, M. (2003) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v64n0108 · Cited by 106
Self-citationCervilla, J. A., Rivera, M., Molina, E., Torres‐González, F., Bellón, J. A., Moreno, B., de Dios Luna, J., Lorente, J. A., de Diego‐Otero, Y., King, M., et al. (2006) · American Journal of Medical Genetics Part B: Neuropsychiatric Genetics · doi:10.1002/ajmg.b.30455 · Cited by 105
Preventing Relapse and Recurrence of Depression:A Brief Review of Therapeutic Options
Thase, M. E. (2006) · CNS Spectrums · doi:10.1017/s1092852900015212 · Cited by 93
Leykin, Y., Amsterdam, J. D., DeRubeis, R. J., Gallop, R., Shelton, R. C., & Hollon, S. D. (2007) · Journal of Consulting and Clinical Psychology · doi:10.1037/0022-006x.75.2.267 · Cited by 82
Self-citationTachyphylaxis in unipolar major depressive disorder
Solomon, D. A., Leon, A. C., Mueller, T. I., Coryell, W., Teres, J. J., Posternak, M. A., Judd, L. L., Endicott, J., & Keller, M. B. (2005) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v66n0302 · Cited by 71
Posternak, M. A., & Zimmerman, M. (2005) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v66n0605 · Cited by 67
Fluoxetine efficacy in treatment resistant depression
Amsterdam, J. D., Maislin, G., & Potter, L. S. (1994) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/0278-5846(94)90057-4 · Cited by 62 · cited 1×
“Tachyphylaxis may also occur in a stepwise fashion after repeated courses of antidepressant drug therapy [”
BackgroundSelf-citationSharma, V. (2001) · Journal of Affective Disorders · doi:10.1016/s0165-0327(00)00212-3 · Cited by 54 · cited 1×
“Tachyphylaxis, or tolerance to antidepressant drug therapy, generally refers to the gradual loss of antidepressant efficacy during long-term use [”
BackgroundMichelson, D., Adler, L. A., Amsterdam, J. D., Dunner, D. L., Nierenberg, A. A., Reimherr, F. W., Schatzberg, A. F., Kelsey, D. K., & Williams, D. W. (2007) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v68n0414 · Cited by 51
Self-citationMolecular mechanisms of tolerance to and withdrawal of GABAA receptor modulators
Biggio, G., Dazzi, L., Biggio, F., Mancuso, L., Talani, G., Busonero, F., Mostallino, M. C., Sanna, E., & Follesa, P. (2003) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2003.08.002 · Cited by 43
Venlafaxine and treatment-resistant depression
Thase, M. E., Friedman, E. S., & Howland, R. H. (2000) · Depression and Anxiety · doi:10.1002/1520-6394(2000)12:1+<55::aid-da7>3.0.co;2-x · Cited by 38
Zimmerman, M., & Thongy, T. (2007) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v68n0814 · Cited by 31
Bonavita, C. D., Bisagno, V., Bonelli, C. G., Acosta, G. B., Rubio, M. C., & Wikinski, S. I. (2002) · Neuropharmacology · doi:10.1016/s0028-3908(02)00012-6 · Cited by 19
Augmentation strategies to increase antidepressant tolerability.
Zajecka, J. (2007) · PubMed · Cited by 11
Research works printed but not linked: 7
- 10.1016%2fj.jad.2005.06.011 · DOI
- 10.4088%2fjcp.v68n1014 · DOI · Paper page
- 10.4088%2fjcp.1007e23 · doi:10.4088/jcp.1007e23
- 10.1016%2f0306-9877%2884%2990018-5 · DOI · Paper page
- 10.1176%2fappi.ajp.163.11.1905 · doi:10.1176/appi.ajp.163.11.1905 · Paper page
- 10.1176%2fappi.ajp.163.7.1161 · doi:10.1176/appi.ajp.163.7.1161 · Paper page
- 10.1176%2fappi.ajp.163.9.1531 · DOI
Cited by
Treatment selection in depression.
Cohen, Z. D., & DeRubeis, R. J. (2018) · Annual Review of Clinical Psychology · doi:10.1146/annurev-clinpsy-050817-084746 · Cited by 435
“Prior exposure to ADMs and history of nonresponse to ADMs have each been found consistently to predict poor response to future courses of antidepressants (Amsterdam et al. 2009, 2016; Amsterdam & Shults 2009; Byrne & Rothschild 1998).”
BackgroundBaldessarini, R. J. (2013) · doi:10.1007/978-1-4614-3710-9 · Cited by 365
Kim, T., Xu, C., & Amsterdam, J. D. (2019) · Journal of Affective Disorders · doi:10.1016/j.jad.2019.03.028 · Cited by 190
Self-citationRoss, E. L., Zivin, K., & Maixner, D. F. (2018) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2018.0768 · Cited by 150
The mechanisms of tolerance in antidepressant action
Fava, G. A., & Offidani, E. (2011) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2010.07.026 · Cited by 158
“Followinga8 week, randomized, double-blind study comparing the efficacy and tolerability of escitalopram (10–20 mg/day; N=148) to that of venlafaxine extended release (75–150 mg/day; N=145) in primary care patients with MDD, at the end of the 1 week run-out period (week 9), a total of 23 symptoms were reported on the…”
Influential
Metadata
- Authors
- Amsterdam, J. D., Williams, D., Michelson, D., Adler, L. A., Dunner, D. L., Nierenberg, A. A., Reimherr, F. W., & Schatzberg, A. F.
- Affiliations
- University of Pennsylvania (US)
- Eli Lilly (United States) (US)
- Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
- New York University (US)
- Harvard University (US)
- University of Utah (US)
- Stanford Medicine (US)
- Venue
- Neuropsychobiology
- Publisher
- S. Karger AG
- Published
- 2009
- Volume
- 59
- Issue
- 4
- Pages
- 227-233
- ISSN
- 0302-282X (ISSN-L)
- 1423-0224
- OpenAlex
- W2014544184
- Cited by
- 39
- References
- 39
- Citations by year
- 2025: 3 · 2024: 1 · 2023: 1 · 2022: 1 · 2021: 2 · 2020: 4 · 2019: 5 · 2018: 5 · 2016: 1 · 2015: 1 · 2014: 2 · 2013: 2 · 2012: 3
- FWCI
- 2.63
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.karger.com/Services/SiteLicenses (vor)
- www.karger.com/Services/SiteLicenses (tdm)
- Locations
- Neuropsychobiology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Social Sciences › Psychology › Experimental and Cognitive Psychology › Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
- Keywords
- tachyphylaxis, antidepressant resistance, recurrent major depressive disorder, sertraline, atomoxetine, treatment response, continuation treatment, selective serotonin reuptake inhibitors
- MeSH terms
- Atomoxetine Hydrochloride, Antidepressive Agents, Major Depressive Disorder, Double-Blind Method, Drug Therapy, Combination, Female, Humans, Male, Propylamines, Recurrence, Tachyphylaxis, Logistic Models, Odds Ratio, Treatment Outcome, Adrenergic Uptake Inhibitors, Sertraline
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.